Projects per year
Personal profile
Area of Expertise
A new approach involving drug delivery to cancerous breast tumors is proposed. The method involves the encapsulation of an anti-cancer agent (such as taxol [pacliataxel]) into artificial cholesterol complexes as novel delivery vehicles. These complexes resemble high density lipoproteins (good cholesterol carriers, HDL) and they markedly improve the solubility and transportability of otherwise poorly soluble drugs. The proposed studies include: Testing of the HDL/drug complexes against several breast tumor cells, by comparing their killing potential to that of the free drug and testing the efficacy of the HDL/drug preparation against breast tumors carried by mice (in vivo). Future studies would include clinical trials with appropriate formulations.
If successful, these studies will establish a new generation of chemotherapeutic agents against breast cancer and thus substantially enhance the quality of life and the survival of patients. Furthermore, the proposed formulation may provide an improved treatment modality for breast cancer as the encapsulated drug preparation is expected to have reduced toxicity against normal cells and tissues (particularly heart tissue). This approach has the potential to markedly improve the delivery of anticancer drugs to target tissues and thus improve the chemotherapy and may even provide a cure for breast cancer.
If successful, these studies will establish a new generation of chemotherapeutic agents against breast cancer and thus substantially enhance the quality of life and the survival of patients. Furthermore, the proposed formulation may provide an improved treatment modality for breast cancer as the encapsulated drug preparation is expected to have reduced toxicity against normal cells and tissues (particularly heart tissue). This approach has the potential to markedly improve the delivery of anticancer drugs to target tissues and thus improve the chemotherapy and may even provide a cure for breast cancer.
Education/Academic qualification
PhD in Biochemistry, University of Washington
Award Date: 1 Jan 2002
MS in Microbiology, University of British Columbia
Award Date: 1 Jan 2001
BS in Food Technology, University of British Columbia
Award Date: 1 Jan 2000
Fingerprint Dive into the research topics where Andras Lacko is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 2 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 8 Finished
Reconstituted High Density Lipoprotein Particles as siRNA Carriers
1/07/17 → 30/06/18
Project: Research
Targeting the Plasma High Density Lipoprotein Receptor (SR-B1) for Effective Anti-Cancer Therapeutics
1/03/16 → 1/03/17
Project: Research
Selective Tumor Delivery of Anti-Cancer Agents in Ovarian Cancer Therapy
Cancer Prevention & Res Inst of TX
1/12/14 → 30/05/18
Project: Research
Research Output
[ 99 mTc-HYNIC-N-dodecylamide]:a new hydrophobic tracer for labelling reconstituted high-density lipoproteins (rHDL) for radioimaging
Isaac-Olivé, K., Ocampo-García, B. E., Aranda-Lara, L., Santos-Cuevas, C. L., Jiménez-Mancilla, N. P., Luna-Gutiérrez, M. A., Medina, L. A., Nagarajan, B., Sabnis, N., Raut, S., Prokai, L. & Lacko, A. G., 14 Jan 2019, In : Nanoscale. 11, 2, p. 541-551 11 p.Research output: Contribution to journal › Article
1
Scopus
citations
Identifying and targeting angiogenesis-related microRNAs in ovarian cancer
Chen, X., Mangala, L. S., Mooberry, L., Bayraktar, E., Dasari, S. K., Ma, S., Ivan, C., Court, K. A., Rodriguez-Aguayo, C., Bayraktar, R., Raut, S., Sabnis, N., Kong, X., Yang, X., Lopez-Berestein, G., Lacko, A. G. & Sood, A. K., 15 Aug 2019, In : Oncogene. 38, 33, p. 6095-6108 14 p.Research output: Contribution to journal › Article
3
Scopus
citations
The SR-B1 Receptor as a Potential Target for Treating Glioblastoma
Berney, E., Sabnis, N., Panchoo, M., Raut, S., Dickerman, R. & Lacko, A. G., 1 Jan 2019, In : Journal of Oncology. 2019, 1805841.Research output: Contribution to journal › Article
Open Access
2
Scopus
citations
Lipoproteins for therapeutic delivery: Recent advances and future opportunities
Raut, S., Dasseux, J. L., Sabnis, N. A., Mooberry, L. & Lacko, A., 1 Jan 2018, In : Therapeutic Delivery. 9, 4, p. 257-268 12 p.Research output: Contribution to journal › Review article
7
Scopus
citations
Reconstituted HDL: Drug delivery platform for overcoming biological barriers to cancer therapy
Raut, S., Mooberry, L., Sabnis, N., Garud, A., Dossou, A. S. & Lacko, A., 15 Oct 2018, In : Frontiers in Pharmacology. 9, OCT, 01154.Research output: Contribution to journal › Review article
4
Scopus
citations